The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | The key barrier to making the implementation of bispecific antibodies in CLL possible
In this video, Parag Jasani, FRCPath, MBBS, MRCP, Royal Free London NHS Foundation Trust, London, UK, briefly highlights the main barrier to implementing bispecific antibodies in the treatment of chronic lymphocytic leukemia (CLL). This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
CLL is quite underserved with bispecific antibodies. The clinical trial data is just emerging so we have to wait for that to mature and obviously we need to look at the safety signals before it’s widely available to everyone. I think toxicity is the main one. For CLL, patients are generally elderly so we’ve got to be careful with all these agents that they’re not too toxic...
CLL is quite underserved with bispecific antibodies. The clinical trial data is just emerging so we have to wait for that to mature and obviously we need to look at the safety signals before it’s widely available to everyone. I think toxicity is the main one. For CLL, patients are generally elderly so we’ve got to be careful with all these agents that they’re not too toxic. But I mentioned to you with the new technology coming on, you know, there may be ways to mitigate the toxicity.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
